Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

In the latest session, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $7.99 down -0.13% from its previous closing price of $8.0. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 1.3 million shares were traded. AMLX stock price reached its highest trading level at $8.18 during the session, while it also had its lowest trading level at $7.86.

Ratios:

For a deeper understanding of Amylyx Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.72 and its Current Ratio is at 8.72. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.

On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.

On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 13 ’25 when Mazzariello Gina sold 15,000 shares for $8.34 per share. The transaction valued at 125,046 led to the insider holds 156,969 shares of the business.

Mazzariello Gina sold 15,000 shares of AMLX for $121,102 on Aug 12 ’25. The Chief Legal Officer now owns 171,969 shares after completing the transaction at $8.07 per share. On Aug 12 ’25, another insider, GINA MAZZARIELLO, who serves as the Officer of the company, bought 30,000 shares for $7.82 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 713339200 and an Enterprise Value of 537583808. Its current Enterprise Value per Revenue stands at -2158.971 whereas that against EBITDA is -2.739.

Stock Price History:

The Beta on a monthly basis for AMLX is -0.46, which has changed by 2.5353982 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $8.72, while it has fallen to a 52-week low of $2.05. The 50-Day Moving Average of the stock is 11.95%, while the 200-Day Moving Average is calculated to be 59.26%.

Shares Statistics:

For the past three months, AMLX has traded an average of 1.42M shares per day and 841630 over the past ten days. A total of 89.16M shares are outstanding, with a floating share count of 66.52M. Insiders hold about 25.43% of the company’s shares, while institutions hold 84.75% stake in the company. Shares short for AMLX as of 1753920000 were 7192631 with a Short Ratio of 5.05, compared to 1751241600 on 6622803. Therefore, it implies a Short% of Shares Outstanding of 7192631 and a Short% of Float of 8.8999994.

Earnings Estimates

Amylyx Pharmaceuticals Inc (AMLX) is currently under the scrutiny of 6.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.28 and low estimates of -$0.53.

Analysts are recommending an EPS of between -$1.68 and -$2.04 for the fiscal current year, implying an average EPS of -$1.85. EPS for the following year is -$1.47, with 6.0 analysts recommending between -$0.96 and -$1.97.